Access Aims to Develop Oral Drug-Delivery Technology for RNAi Therapeutics | GenomeWeb

By Doug Macron

Access Pharmaceuticals last week announced that it has begun an in-house effort to adapt its proprietary vitamin B12-based technology for therapeutic RNAi applications and potentially develop orally delivered drugs.

The technology, dubbed Cobalamin, is based on the body's natural vitamin B12 uptake mechanism, Access CEO Jeff Davis told RNAi News this week. It involves merging a polymer and active pharmaceutical ingredient to make a nanoparticle, which is then coated with the vitamin.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.